BTCC
/
BTCC Square
/
Global Cryptocurrency
/
GSK Re-enters Cancer Drugs Market in India with Two Gynaecology Treatments
GSK Re-enters Cancer Drugs Market in India with Two Gynaecology Treatments
6
1
BTCCSquare news:
GlaxoSmithKline Pharmaceuticals is marking its return to India's oncology sector with the introduction of Jemperli (dostarlimab) and Zejula (niraparib). The drugs will be priced on a tiered system tailored to the Indian market, according to company executives. This MOVE follows GSK's 2014 global asset swap with Novartis, which involved a $20 billion-plus exchange and reshaped its portfolio in India.
The new offerings focus on precision medicine, with Jemperli targeting advanced endometrial cancer through PD-1 immunotherapy. A patient assistance program named Phoenix has been established to improve accessibility. Both products will initially be imported, though pricing details remain undisclosed.
By:
